|EP108-C01||Pre-coated Human ACE2 Microplate||1 plate|
|EP108-C02||SARS-CoV-2 Inhibitor||10 μg|
|EP108-C03||HRP-SARS-CoV-2 Spike RBD(B.1.1.7)||15 μg|
|EP108-C04||10xWashing Buffer||50 mL|
|EP108-C05||Dilution Buffer||50 mL|
|EP108-C06||Substrate Solution||12 mL|
|EP108-C07||Stop Solution||7 mL|
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Your experiment will include 5 simple steps:
a)All reagents were returned to room temperature(20℃-25℃) before use.
b)Make series the tested sample and control with ditlution buffer,HRP-SARS-CoV-2 RBD diluted with dilution buffer.
c) Add the diluted sample ,Control and the HRP-SARS-CoV-2 RBD add the plate respectively.
d) Wash the plate and add TMB or other colorimetric HRP substrate. e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Inhibition of HRP-SARS-CoV-2 Spike RBD(B.1.1.7):SARS-CoV-2 Spike RBD Binding by SARS-CoV-2 inhibitor.
Serial dilutions of SARS-CoV-2 inhibitor (Catalog # EP108-C02) (1:1 serial dilutions, from 5.0ug/mL to 0.0098ug/mL) and loaded onto the plate coated by human ACE2 in the presence of HRP-SARS-CoV-2 Spike RBD(B.1.1.7).Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.